Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1996| June  | Volume 17 | Issue 2  
    Online since May 30, 2009

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Results of MCP841 all protocol for patients with lymphoblastic lymphomas cancer institute experience.
K Kalaichelvi, SG Raman, V Maitreyan, S Devarajan, TG Sagar, V Shantha, Kalaichelvi Kannan
June 1996, 17(2):85-89
23 patients upto and inclusive of 25 years, diagnosed as lymphoblastic lymphoma from january 1983 to January 1994,treated with MCP841 ALL protocol at the Cancer Institute (WIA), Madras, showed a 91 complete response rate and a 55.8 and 51 RFS and EFS respectively at the end of 5 years and remaining the same at 10 years.
[ABSTRACT]   Full text not available   
  682 0 -
Mine therapy for patients with resistant or relapsed or relapsed non hodgkins lymphoma.
R Nair, G Ramakrishnan, TK Saika, SS Chitralekha, SR Joshi, AH Suresh, Nair Reena
June 1996, 17(2):90-98
Twenty five patients with resistant or relapsed Non Hodgkins lymphoma were treated with a combination of mesna with iphosphamide,nonvantrone(mitozantrone),and etoposide(MINE). All patients had previously been treated with a combination of methotrexate, doxorubicin,cyclophosphamide.oncovin, prednisolone, and bleomycin(MACOP-B). Complete remission was obtained in 9(36)and the overall response was 72. The median survival for patients achieving a complete remission was 21 months and for patients with a partial response was 7.5 months(p=0.003). The regimen was well tolerated and myelosuppression was the commonest toxicity. There were no treatment related deaths. The stage of disease, presence of symptoms,bulk of the tumor and histology at initial presentation had no impact on survival. The response to intial therapy and disease free interval after the first line chemotherapy were significantly associated with response to MINE and survival.
[ABSTRACT]   Full text not available   
  660 0 -
Leukoencephalopathy following single dose of intrathecal methotrexate in a child with acute lymphoblastic leukemia.
SJ Vaidya, SK Pai, PM Parikh, CN Nair, PA Kurkure, SH Advani
June 1996, 17(2):102-106
Intrathecal Methotrexate forms an integral part of presymptomatic therapy for central nervous system leukemia in acute lymphoblastic leukemia. Here we report a case of ALL with an unusual complication in the form of leukoencephalopathy after a single dose of intrathecal methotrexarte in the absence of CNS leukemia. The patient had a complete neurological recovery and his further antileukemic therapy was given without cranial radiotherapy and intrthecal methotrexate. The patient has been in complete remission for the past 30 months and neurologically normal.
[ABSTRACT]   Full text not available   
  659 0 -
Phenotypic shift of lymphoid blasts at relapse -a case report.
S Bajpai, CK Nair, PA Kurkure, SA Barbhaya, SH Advani
June 1996, 17(2):111-113
A thirteen year old child with acute lymphoblastic leukemia was found to have only HLA-DR and Immunolglobin heavy chain rearrangement at presentation. After first remission she relapsed with common acute lymphoblastic leukemia antigen positive blasts. Alterations of blast cell phenotype is nwo common in acute lymphoblastic leukemia however, accquiring of the CALL antigen at relapse is rare. The biology of the shifts in phenotype are discussed.
[ABSTRACT]   Full text not available   
  650 0 -
TAL-1 deletion in T cell acute lymphoblastic leukemia implications in the detection of minimal residual disease.
K Nirmala, K Kalaichelvi, KR Rajalakshmi, SG Raman, Dongen JJM Van, V Shantha, T Rajkumar
June 1996, 17(2):79-84
Conclusion: The greatest utility of the TAL-1 deletion is in the detection of MRD by PCR in T-ALL. The association with clinical and CD3 immunophenotype warrants studies in greater number of patients.
[ABSTRACT]   Full text not available   
  643 0 -
Richter's syndrome in chronic lymphatic leukemia.
R Mehrotra, D Heaton
June 1996, 17(2):99-101
Richter's syndrome is an unusual complication of chronic lymphatic leukaemia. Its development is usually terminal in patients with a known history of chronic lymphatic leukaemia. It is characterized by fever, weight loss, lymphatdenopathy, hepatosplenomegaly, dysgobulinaemia and a pelomorphic malignant lymphoma. It is debatable whether the large cell lymphomas arise de-novo or as a result of transformation of the pre-existing leukaemia. We describe a 52 year old patient with Richter's syndrome.
[ABSTRACT]   Full text not available   
  585 0 -
Sickle beta thalassemia with acute myeloid leukemia(FAB-M4)and orbital chloromas.
ML Srinivas, D Raghunadharao, K Gayathri
June 1996, 17(2):107-110
We report the management of a case of Sickle B Thalassemia with acute myeloid leukemia. This association has not been reported in literature so far.
[ABSTRACT]   Full text not available   
  565 0 -
Topotecan
BB Parekh
June 1996, 17(2):114-116
Full text not available   
  281 0 -
  Feedback 
  Subscribe